FINNENCE ▪ THE WIRE FILE
THE WIRE · № 84035
Company▼ Bearish
Phase 3 results posted: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma — Nektar Therapeutics
KINDCompany
DIRECTION▼ Bearish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A terminated NKTR-255 trial with only 15 patients enrolled is a clinical setback for Nektar.
Terminated oncology trial weakens Nektar's pipeline case
CATALYST TO WATCH
Pipeline reprioritization or partnership news
MAIN RISK
Further pipeline attrition possible
FULL DISPATCH
Sponsor: Nektar Therapeutics; Status: Terminated; Conditions: Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma; Interventions: NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg; Enrollment: 15 (actual); First posted: 2022-12-23; Results posted: 2026-10-16; NCT: NCT05664217
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin — Eli Lilly and Company2026-10-16 12:00 UTC
Phase 3 results posted: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin — Eli Lilly and Company2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis — Eli Lilly and Company2026-10-16 12:00 UTC
Phase 3 results posted: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis — Eli Lilly and Company2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement2026-10-16 12:00 UTC
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Withings BodyScan 2 Named One of TIME's Best Inventions of 20262026-10-16 12:00 UTC
Withings BodyScan 2 Named One of TIME's Best Inventions of 20262026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors2026-10-16 12:00 UTC
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma2026-10-16 12:00 UTC
Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma2026-10-16 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.